Reducing Surgical Stenosis for Patients with Kidney Disease
How Vascular Therapies is Addressing the Need
Sirogen™
Vascular Therapies’ approach is to deliver sirolimus (a drug) locally to the blood vessel at and around the anastomosis. It is doing so by implanting a collagen-based drug delivery system containing sirolimus (SirogenTM) at the time of the surgical procedure. Vascular Therapies’ goal is to prevent the vein from narrowing and provide adequate blood flow to support consistent dialysis.
Caution: FDA has tentatively approved the proprietary tradename Sirogen™ for Vascular Therapies’ formulation of sirolimus. Sirogen™ is an investigational product that is not available for sale in any country.